TapewireFind a company

person · Reporting owner

HENDERSON JOHN T

Disclosed activity across 2 companies

Tapewire entity
30156
SEC CIK
0001226488

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CYTOKINETICS INCCYTK · Entity 3528DirectorJuly 15, 2026July 16, 2026
MYRIAD GENETICS INCMYGN · Entity 5953DirectorDecember 05, 2019December 06, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CYTOKINETICS INC

Report date July 15, 2026 · Filed July 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect78,360 Reported balance After 2026-07-15 transaction · row 1
1 source row

Row 1 · 2026-07-15 · Grant · Acquired 272 · Balance 78,360

F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Common StockSEC Table I · non-derivativeIndirectby Spouse83 Reported balance Holding disclosure · report date 2026-07-15 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 83

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

MYRIAD GENETICS INC

Report date December 05, 2019 · Filed December 06, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect76,040 Reported balance After 2019-12-05 transaction · row 1
1 source row

Row 1 · 2019-12-05 · Grant · Acquired 11,687 · Balance 76,040

F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant.

Common StockSEC Table I · non-derivativeIndirectby Spouse2,050 Reported balance Holding disclosure · report date 2019-12-05 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,050

Filing footnotes · ownership attribution and instrument terms

F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 15, 2026 Filed Jul 16, 2026 20:31 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 272 $82.62 $22,472.64
Disclosure

SEC source: 0001061983-26-000080 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,360

F1 · kind: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Read SEC document
May 27, 2026 Filed May 27, 2026 23:12 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 4,301 $0.00 Strike: $77.15 $0.00
Disclosure

SEC source: 0001061983-26-000059 · form4.xml · derivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,301

Underlying: Common Stock · 4,301 shares

Expires 2036-05-26

Read SEC document
May 27, 2026 Filed May 27, 2026 23:12 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 2,851 $0.00 $0.00
Disclosure

SEC source: 0001061983-26-000059 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,088

Read SEC document
May 05, 2026 Filed May 5, 2026 20:15 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $7.61 $0.00
Disclosure

SEC source: 0001061983-26-000048 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2026-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 05, 2026 Filed May 5, 2026 20:15 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 20,000 $75.97 $1,519,400.00
Disclosure

SEC source: 0001061983-26-000048 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,237

Read SEC document
May 05, 2026 Filed May 5, 2026 20:15 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 20,000 $7.61 $152,200.00
Disclosure

SEC source: 0001061983-26-000048 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 15, 2026 Filed Apr 15, 2026 22:34 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 325 $65.37 $21,245.25
Disclosure

SEC source: 0001061983-26-000039 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,237

F1 · kind: Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested.

Read SEC document
January 15, 2026 Filed Jan 16, 2026 21:17 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 334 $63.44 $21,188.96
Disclosure

SEC source: 0001061983-26-000005 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,912

F1 · kind: Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors.

Read SEC document
December 02, 2025 Filed Dec 2, 2025 22:14 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 8,750 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001061983-25-000042 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,750 shares

Expires 2026-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 02, 2025 Filed Dec 2, 2025 22:14 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 8,750 $63.90 $559,125.00
Disclosure

SEC source: 0001061983-25-000042 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,578

Read SEC document
December 02, 2025 Filed Dec 2, 2025 22:14 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 8,750 $10.00 $87,500.00
Disclosure

SEC source: 0001061983-25-000042 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 15, 2025 Filed Oct 16, 2025 20:36 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 338 $62.80 $21,226.40
Disclosure

SEC source: 0001061983-25-000012 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,578

F1 · kind: Director equity in lieu of cash retainer program.

Read SEC document
July 15, 2025 Filed Jul 16, 2025 21:48 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 559 $38.01 $21,247.59
Disclosure

SEC source: 0001127602-25-019293 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,240

F1 · kind: Director equity in lieu of cash retainer program.

Read SEC document
May 14, 2025 Filed May 14, 2025 23:40 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 10,880 $0.00 Strike: $30.00 $0.00
Disclosure

SEC source: 0001127602-25-014364 · form4.xml · derivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,880

Underlying: Common Stock · 10,880 shares

Expires 2035-05-13

F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors.

Read SEC document
May 14, 2025 Filed May 14, 2025 23:40 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 7,333 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-014364 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,681

F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting.

Read SEC document
April 15, 2025 Filed Apr 16, 2025 20:25 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $6.21 $0.00
Disclosure

SEC source: 0001127602-25-012129 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2025-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 15, 2025 Filed Apr 16, 2025 20:25 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 3,190 $38.66 $123,325.40
Disclosure

SEC source: 0001127602-25-012129 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,348

Read SEC document
April 15, 2025 Filed Apr 16, 2025 20:25 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 20,000 $6.21 $124,200.00
Disclosure

SEC source: 0001127602-25-012129 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 15, 2025 Filed Apr 16, 2025 20:07 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 551 $38.56 $21,246.56
Disclosure

SEC source: 0001127602-25-012117 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,348

F1 · kind: Shares acquired pursuant to Director Stock in lieu of Cash Retainer Program.

Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:27 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 434 $48.93 $21,235.62
Disclosure

SEC source: 0001127602-25-000771 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,987

F1 · kind: Director Stock in Lieu of Cash Retainer Program

Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:05 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 10,092 $0.00 Strike: $7.37 $0.00
Disclosure

SEC source: 0001127602-24-029248 · form4.xml · derivative · entry 6

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,092 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:05 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 1,780 $0.00 Strike: $7.37 $0.00
Disclosure

SEC source: 0001127602-24-029248 · form4.xml · derivative · entry 5

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,092

Underlying: Common Stock · 1,780 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:05 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 10,092 $7.37 $74,378.04
Disclosure

SEC source: 0001127602-24-029248 · form4.xml · nonDerivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,553

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:05 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 1,780 $50.42 $89,747.60
Disclosure

SEC source: 0001127602-24-029248 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,461

Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:05 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 1,780 $7.37 $13,118.60
Disclosure

SEC source: 0001127602-24-029248 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,241

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 01, 2024 Filed Oct 3, 2024 21:27 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 403 $52.60 $21,197.80
Disclosure

SEC source: 0001127602-24-025196 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,461

F1 · kind: Stock award in lieu of cash retainer payment.

Read SEC document
July 01, 2024 Filed Jul 4, 2024 00:02 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 388 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-020146 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,058

F1 · kind: Stock award in lieu of cash retainer payment.

Read SEC document
May 15, 2024 Filed May 16, 2024 22:04 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 3,636 $0.00 Strike: $60.50 $0.00
Disclosure

SEC source: 0001127602-24-015722 · form4.xml · derivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,636

Underlying: Common Stock · 3,636 shares

Expires 2034-05-15

Read SEC document
May 15, 2024 Filed May 16, 2024 22:04 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 5,600 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-015722 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,670

Read SEC document
April 25, 2024 Filed Apr 25, 2024 22:54 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 10,562 $64.54 $681,671.48
Disclosure

SEC source: 0001127602-24-013411 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,070

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
February 14, 2024 Filed Feb 14, 2024 21:04 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $4.44 $0.00
Disclosure

SEC source: 0001127602-24-004994 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2024-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
February 14, 2024 Filed Feb 14, 2024 21:04 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 5,000 $76.48 $382,400.00
Disclosure

SEC source: 0001127602-24-004994 · form4.xml · nonDerivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,632

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
February 14, 2024 Filed Feb 14, 2024 21:04 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 5,000 $4.44 $22,200.00
Disclosure

SEC source: 0001127602-24-004994 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,632

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
January 12, 2024 Filed Jan 12, 2024 22:20 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $4.44 $0.00
Disclosure

SEC source: 0001127602-24-001286 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2024-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
January 12, 2024 Filed Jan 12, 2024 22:20 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 5,000 $85.14 $425,700.00
Disclosure

SEC source: 0001127602-24-001286 · form4.xml · nonDerivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,632

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
January 12, 2024 Filed Jan 12, 2024 22:20 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 5,000 $4.44 $22,200.00
Disclosure

SEC source: 0001127602-24-001286 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,632

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

Read SEC document
January 02, 2024 Filed Jan 3, 2024 21:21 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 252 $84.12 $21,198.24
Disclosure

SEC source: 0001127602-24-000425 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,632

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $84.12, representing the closing stock price of the Issuer's common stock on January 2, 2024.

Read SEC document
December 18, 2023 Filed Dec 19, 2023 21:12 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 13,020 $0.00 Strike: $6.72 $0.00
Disclosure

SEC source: 0001127602-23-030007 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,020 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

F2 · kind: Sell-to-cover transaction. Dr. Henderson acquired a net 10,562 shares of common stock, which he continues to hold.

Read SEC document
December 18, 2023 Filed Dec 19, 2023 21:12 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 2,458 $36.34 $89,323.72
Disclosure

SEC source: 0001127602-23-030007 · form4.xml · nonDerivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,380

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

F2 · kind: Sell-to-cover transaction. Dr. Henderson acquired a net 10,562 shares of common stock, which he continues to hold.

Read SEC document
December 18, 2023 Filed Dec 19, 2023 21:12 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 13,020 $6.72 $87,494.40
Disclosure

SEC source: 0001127602-23-030007 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023.

F2 · kind: Sell-to-cover transaction. Dr. Henderson acquired a net 10,562 shares of common stock, which he continues to hold.

Read SEC document
October 02, 2023 Filed Oct 3, 2023 20:18 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 762 $27.88 $21,244.56
Disclosure

SEC source: 0001127602-23-025181 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,818

F1 · shares: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $27.88, representing the closing stock price of the Issuer's common stock on October 2, 2023.

Read SEC document
July 03, 2023 Filed Jul 5, 2023 20:20 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 636 $33.36 $21,216.96
Disclosure

SEC source: 0001127602-23-020048 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,056

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $33.36, representing the closing stock price of the Issuer's common stock on July 3, 2023.

Read SEC document
May 15, 2023 Filed May 15, 2023 20:07 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 4,166 $0.00 Strike: $6.78 $0.00
Disclosure

SEC source: 0001127602-23-015541 · form4.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,166 shares

Expires 2023-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2022.

Read SEC document
May 15, 2023 Filed May 15, 2023 20:07 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 4,166 $37.77 $157,349.82
Disclosure

SEC source: 0001127602-23-015541 · form4.xml · nonDerivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,420

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2022.

Read SEC document
May 15, 2023 Filed May 15, 2023 20:07 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 4,166 $6.78 $28,245.48
Disclosure

SEC source: 0001127602-23-015541 · form4.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2022.

Read SEC document
May 10, 2023 Filed May 18, 2023 20:49 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $37.89 $0.00
Disclosure

SEC source: 0001127602-23-016169 · form4.xml · derivative · entry 3

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-10

F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024.

Read SEC document
May 10, 2023 Filed May 18, 2023 20:49 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 5,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-016169 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,420

F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024.

Read SEC document
April 03, 2023 Filed Apr 5, 2023 20:09 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 530 $37.71 $19,986.30
Disclosure

SEC source: 0001127602-23-012552 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,420

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 23:24 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 450 $44.35 $19,957.50
Disclosure

SEC source: 0001127602-23-000692 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,890

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $44.35, representing the closing stock price of the Issuer's common stock on January 3, 2023.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 20:20 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 391 $51.11 $19,984.01
Disclosure

SEC source: 0001127602-22-023698 · form4.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,440

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2011.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.